AstraZeneca, a global biopharmaceutical and biotechnology company, is looking to uncover innovative methods for tissue-specific delivery as well as selective tissue-specific expression or regulation that can substantially enhance the therapeutic efficacy and safety profile of their novel molecules.
The potential for treating devastating diseases that affect CNS, kidney, or muscle tissues has been constrained by the absence of targeted tissue-specific delivery, expression or regulation methods.
AstraZeneca is seeking innovative approaches for the targeted...